Department of Molecular Pharmaceutics, University of Utah, Salt Lake City, Utah 84112, United States.
Guangdong Provincial Engineering Research Center of Molecular Imaging, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong 519000, China.
Acc Chem Res. 2024 Jun 18;57(12):1649-1657. doi: 10.1021/acs.accounts.3c00772. Epub 2024 May 25.
ConspectusFacilitated by the unique triple-helical protein structure, fibrous collagens, the principal proteins in animals, demonstrate a dual function of serving as building blocks for tissue scaffolds and as a bioactive material capable of swift renewal in response to environmental changes. While studies of triple-helical collagen mimetic peptides (CMPs) have been instrumental in understanding the molecular forces responsible for the folding and assembly of triple helices, as well as identifying bioactive regions of fibrous collagen molecules, single-strand CMPs that can specifically target and hybridize to denatured collagens (i.e., collagen hybridizing peptides, CHPs) have proven useful in identifying the remodeling activity of collagen-rich tissues related to development, homeostasis, and pathology. Efforts to improve the utility of CHPs have resulted in the development of new skeletal structures, such as dimeric and cyclic CHPs, as well as the incorporation of artificial amino acids, including fluorinated proline and N-substituted glycines (peptoid residues). In particular, dimeric CHPs were used to capture collagen fragments from biological fluid for biomarker study, and the introduction of peptoid-based collagen mimetics has sparked renewed interest in peptidomimetic research because peptoids enable a stable triple-helical structure and the presentation of an extensive array of side chain structures offering a versatile platform for the development of new collagen mimetics.This Account will cover the evolution of our research from CMPs as biomaterials to ongoing efforts in developing triple-helical peptides with practical theranostic potential in targeting denatured and damaged collagens. Our early efforts in functionalizing natural collagen scaffolds via noncovalent modifications led to the discovery of an entirely new use of CMPs. This discovery resulted in the development of CHPs that are now used by many different laboratories for the investigation of pathologies associated with changes in the structures of extracellular matrices including fibrosis, cancer, and mechanical damage to collagen-rich, load-bearing tissues. Here, we delve into the essential design features of CHPs contributing to their collagen binding properties and practical usage and explore the necessity for further mechanistic understanding of not only the binding processes (e.g., binding domain and stoichiometry of the hybridized complex) but also the biology of collagen degradation, from proteolytic digestion of fibrils to cellular processing of collagen fragments. We also discuss the strengths and weaknesses of peptoid-based triple-helical peptides as applied to collagen hybridization touching on thermodynamic and kinetic aspects of triple-helical folding. Finally, we highlight current limitations and future directions in the use of peptoid building blocks to develop bioactive collagen mimetics as new functional biomaterials.
由独特的三螺旋蛋白质结构促成,纤维胶原作为动物的主要蛋白质,具有双重功能,既可以作为组织支架的构建块,又可以作为一种生物活性材料,能够迅速响应环境变化进行更新。尽管对三螺旋胶原模拟肽(CMP)的研究对于理解导致三螺旋折叠和组装的分子力以及识别纤维胶原分子的生物活性区域非常有帮助,但能够特异性靶向和杂交变性胶原的单链 CMP(即胶原杂交肽,CHP)已被证明在鉴定与发育、动态平衡和病理学相关的富含胶原组织的重塑活性方面非常有用。为了提高 CHP 的实用性,人们努力开发了新的骨骼结构,如二聚体和环状 CHP,以及人工氨基酸的掺入,包括氟化脯氨酸和 N-取代甘氨酸(肽类残基)。特别是,二聚体 CHP 用于从生物流体中捕获胶原片段以进行生物标志物研究,而基于肽类的胶原模拟物的引入重新激发了对肽类模拟物研究的兴趣,因为肽类能够稳定三螺旋结构并呈现广泛的侧链结构,为开发新的胶原模拟物提供了一个多功能平台。本综述将涵盖我们从 CMP 作为生物材料的研究进展,以及目前在开发具有靶向变性和受损胶原的实际治疗潜力的三螺旋肽方面的进展。我们通过非共价修饰对天然胶原支架进行功能化的早期努力导致了对 CMP 的全新用途的发现。这一发现导致了 CHP 的开发,现在许多不同的实验室都在使用 CHP 来研究与细胞外基质结构变化相关的病理学,包括纤维化、癌症以及富含胶原的承重组织的机械损伤。在这里,我们深入探讨了 CHP 对其胶原结合特性和实际用途的重要设计特征,并探讨了不仅需要进一步了解结合过程(例如,杂交复合物的结合域和化学计量),还需要进一步了解胶原降解的生物学,从原纤维的蛋白水解消化到胶原片段的细胞处理。我们还讨论了应用于胶原杂交的基于肽类的三螺旋肽的优缺点,涉及三螺旋折叠的热力学和动力学方面。最后,我们强调了在使用肽类构建块开发新的功能性生物材料作为生物活性胶原模拟物方面的当前限制和未来方向。